(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Nicholas Financial, Onconova Therapeutics, and New York Times.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Nicholas Financial (NICK) | 8.55 | 18.26% | 2023-02-07 19:09:10 |
| 2 | Onconova Therapeutics (ONTX) | 1.34 | 13.56% | 2023-02-08 01:10:34 |
| 3 | New York Times (NYT) | 40.98 | 11.63% | 2023-02-08 15:47:26 |
| 4 | Fortinet (FTNT) | 59.48 | 10.6% | 2023-02-08 15:51:30 |
| 5 | Itau Unibanco (ITUB) | 5.07 | 8.46% | 2023-02-08 15:14:55 |
| 6 | Paylocity Holding Corporation (PCTY) | 232.89 | 6.69% | 2023-02-08 05:06:10 |
| 7 | Uber (UBER) | 36.85 | 5.57% | 2023-02-08 15:50:54 |
| 8 | CME Group (CME) | 187.46 | 5.44% | 2023-02-08 15:55:28 |
| 9 | PGT (PGTI) | 23.38 | 5.41% | 2023-02-08 07:23:18 |
| 10 | PDC Energy (PDCE) | 65.52 | 5.29% | 2023-02-08 05:10:09 |
The three biggest losers today are Lumen Technologies, ParkerVision, and Oxbridge Re Holdings Limited.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Lumen Technologies (LUMN) | 3.91 | -21.74% | 2023-02-08 15:53:05 |
| 2 | ParkerVision (PRKR) | 0.17 | -21.32% | 2023-02-08 10:23:18 |
| 3 | Oxbridge Re Holdings Limited (OXBR) | 2.14 | -13.01% | 2023-02-08 03:10:13 |
| 4 | Inovio Pharmaceuticals (INO) | 1.67 | -10.22% | 2023-02-08 15:58:17 |
| 5 | Nymox Pharmaceutical Corporation (NYMX) | 0.43 | -8.48% | 2023-02-07 22:44:16 |
| 6 | Teva Pharmaceutical (TEVA) | 10.00 | -8.16% | 2023-02-08 15:50:20 |
| 7 | AMC (AMC) | 5.68 | -8.09% | 2023-02-08 15:51:25 |
| 8 | Illumina (ILMN) | 198.48 | -8% | 2023-02-08 15:58:11 |
| 9 | FuboTV (FUBO) | 2.50 | -7.75% | 2023-02-08 15:37:49 |
| 10 | Pacific Biosciences of California (PACB) | 10.39 | -7.69% | 2023-02-08 15:59:58 |
Winners today
1. Nicholas Financial (NICK) – 18.26%
Nicholas Financial, Inc. operates as a consumer finance company in the United States. The company engages in acquiring and servicing automobile finance installment contracts for the purchase of new and used automobiles and light trucks. It also originates direct consumer loans and sells consumer-finance related products. As of March 31, 2021, the company operated 45 branch offices located in Alabama, Florida, Georgia, Illinois, Indiana, Kentucky, Michigan, Missouri, Nevada, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Utah, and Wisconsin. Nicholas Financial, Inc. was founded in 1985 and is headquartered in Clearwater, Florida.
NASDAQ ended the session with Nicholas Financial rising 18.26% to $8.55 on Wednesday, after three consecutive sessions in a row of gains. NASDAQ dropped 1.68% to $11,910.52, following the last session’s upward trend on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, Nicholas Financial has a trailing twelve months EPS of $0.38.
PE Ratio
Nicholas Financial has a trailing twelve months price to earnings ratio of 22.5. Meaning, the purchaser of the share is investing $22.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.67%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nicholas Financial’s stock is considered to be oversold (<=20).
Moving Average
Nicholas Financial’s value is way higher than its 50-day moving average of $6.36 and above its 200-day moving average of $7.86.
Volume
Today’s last reported volume for Nicholas Financial is 23919 which is 459.24% above its average volume of 4277.
Yearly Top and Bottom Value
Nicholas Financial’s stock is valued at $8.55 at 16:32 EST, way below its 52-week high of $11.88 and way higher than its 52-week low of $5.23.
More news about Nicholas Financial.
2. Onconova Therapeutics (ONTX) – 13.56%
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
NASDAQ ended the session with Onconova Therapeutics jumping 13.56% to $1.34 on Wednesday while NASDAQ fell 1.68% to $11,910.52.
Earnings Per Share
As for profitability, Onconova Therapeutics has a trailing twelve months EPS of $-0.846.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.69%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 86.7% and a negative 50%, respectively.
Yearly Top and Bottom Value
Onconova Therapeutics’s stock is valued at $1.34 at 16:32 EST, way below its 52-week high of $2.04 and way higher than its 52-week low of $0.62.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Onconova Therapeutics’s EBITDA is 4.98.
Sales Growth
Onconova Therapeutics’s sales growth is 7.1% for the ongoing quarter and negative 10.7% for the next.
More news about Onconova Therapeutics.
3. New York Times (NYT) – 11.63%
The New York Times Company, together with its subsidiaries, provides news and information for readers and viewers across various platforms worldwide. It offers The New York Times (The Times), a daily and Sunday newspaper in the United States, as well as international edition of The Times; and operates the NYTimes.com Website. The company also transmits articles, graphics, and photographs from The Times and other publications to approximately 1,500 newspapers, magazines, and websites; licenses electronic databases to resellers in the business, professional, and library markets; and offers magazine licensing, news digests, book development, and rights and permissions. In addition, it engages in the live events business, which hosts physical and virtual live events to connect audiences with journalists and outside thought leaders; direct-sold website, mobile application, podcast, email, and video advertisements, as well as digital advertising services; operates Wirecutter, a product review and recommendation products; develops mobile applications, including games and cooking products; prints and distributes products for third parties; and offers other products and services. The company was founded in 1851 and is headquartered in New York, New York.
NYSE ended the session with New York Times rising 11.63% to $40.98 on Wednesday, after two successive sessions in a row of gains. NYSE dropped 0.54% to $15,935.31, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
Earnings Per Share
As for profitability, New York Times has a trailing twelve months EPS of $0.6.
PE Ratio
New York Times has a trailing twelve months price to earnings ratio of 68.3. Meaning, the purchaser of the share is investing $68.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.91%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, New York Times’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
New York Times’s stock is valued at $40.98 at 16:32 EST, way below its 52-week high of $47.67 and way above its 52-week low of $27.59.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 43.5% and a negative 9.3%, respectively.
More news about New York Times.
4. Fortinet (FTNT) – 10.6%
Fortinet, Inc. provides broad, integrated, and automated cybersecurity solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers FortiGate hardware and software licenses that provide various security and networking functions, including firewall, intrusion prevention, anti-malware, virtual private network, application control, web filtering, anti-spam, and wide area network acceleration. The company also provides FortiSwitch product family that offers secure switching solutions for connecting customers their end devices; FortiAP product family, which provides secure wireless networking solutions; FortiExtender, a hardware appliance; FortiAnalyzer product family, which offers centralized network logging, analyzing, and reporting solutions; and FortiManager product family that provides central and scalable management solution for its FortiGate products. It offers FortiWeb product family provides web application firewall solutions; FortiMail product family that secure email gateway solutions; FortiSandbox technology that delivers proactive detection and mitigation services; FortiClient that provides endpoint protection with pattern-based anti-malware, behavior-based exploit protection, web-filtering, and an application firewall; FortiToken and FortiAuthenticator product families for multi-factor authentication to safeguard systems, assets, and data; and FortiEDR/XDR, an endpoint protection solution that provides both comprehensive machine-learning anti-malware execution and real-time post-infection protection. It provides security subscription, technical support, professional, and training services. It sells its security solutions to channel partners and directly to various customers in telecommunications, technology, government, financial services, education, retail, manufacturing, and healthcare industries. It has strategic alliance with Linksys. Fortinet, Inc. was incorporated in 2000 and is headquartered in Sunnyvale, California.
NASDAQ ended the session with Fortinet rising 10.6% to $59.48 on Wednesday while NASDAQ dropped 1.68% to $11,910.52.
Earnings Per Share
As for profitability, Fortinet has a trailing twelve months EPS of $2.96.
PE Ratio
Fortinet has a trailing twelve months price to earnings ratio of 20.12. Meaning, the purchaser of the share is investing $20.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 289.24%.
Moving Average
Fortinet’s value is way above its 50-day moving average of $50.97 and way higher than its 200-day moving average of $53.91.
More news about Fortinet.
5. Itau Unibanco (ITUB) – 8.46%
Itaú Unibanco Holding S.A. offers a range of financial products and services to individuals and corporate customers in Brazil and internationally. The company operates through three segments: Retail Banking, Wholesale Banking, and Activities with the Market and Corporation. It offers various deposit products, as well as loans and credit cards; investment and commercial banking services; real estate lending services; financing and investment services; and leasing and foreign exchange services. The company also provides property and casualty insurance products covering loss, damage, or liabilities for assets or persons, as well as life insurance products covering death and personal accident; and reinsurance products. It serves retail customers, account and non-account holders, individuals and legal entities, high income clients, microenterprises, and small companies. The company was formerly known as Itaú Unibanco Banco Múltiplo S.A. and changed its name to Itaú Unibanco Holding S.A. in April 2009. The company was incorporated in 1924 and is headquartered in São Paulo, Brazil. Itaú Unibanco Holding S.A. is a subsidiary of IUPAR – Itaú Unibanco Participações S.A.
NYSE ended the session with Itau Unibanco jumping 8.46% to $5.07 on Wednesday while NYSE dropped 0.54% to $15,935.31.
Earnings Per Share
As for profitability, Itau Unibanco has a trailing twelve months EPS of $0.35.
PE Ratio
Itau Unibanco has a trailing twelve months price to earnings ratio of 14.31. Meaning, the purchaser of the share is investing $14.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.46%.
More news about Itau Unibanco.
6. Paylocity Holding Corporation (PCTY) – 6.69%
Paylocity Holding Corporation provides cloud-based payroll and human capital management software solutions for medium-sized organizations in the United States. The company offers Payroll and Tax Services solution to simplify payroll, automate processes and manage compliance requirements within one system; expense management, on demand payment, and garnishment solutions; human capital management and employee self-service solutions, document library, compliance dashboard, and HR edge; time and attendance solution, which tracks time and attendance data, eliminating the need for manual tracking of accruals and reducing administrative tasks; schedule tracking services; and time collection devices, including kiosks, time clocks, and mobile and web applications. In addition, the company offers talent management solutions comprising recruiting and onboarding, as well as learning, performance, and compensation management; employee benefits management and third-party administrative solutions; modern workforce solutions consisting of community, premium video, survey, and peer recognition; and analytics and insights solutions covering modern workforce index, data insights, and reporting. Further, it provides implementation and training, client, and tax and regulatory services. The company's clients include for-profit and non-profit organizations across industries, including business services, financial services, healthcare, manufacturing, restaurants, retail, technology, and others. It sells its products through sales representatives. The company was founded in 1997 and is headquartered in Schaumburg, Illinois.
NASDAQ ended the session with Paylocity Holding Corporation jumping 6.69% to $232.89 on Wednesday, following the last session’s upward trend. NASDAQ dropped 1.68% to $11,910.52, following the last session’s upward trend on what was an all-around negative trend trading session today.
Earnings Per Share
As for profitability, Paylocity Holding Corporation has a trailing twelve months EPS of $1.64.
PE Ratio
Paylocity Holding Corporation has a trailing twelve months price to earnings ratio of 142.01. Meaning, the purchaser of the share is investing $142.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.2%.
Yearly Top and Bottom Value
Paylocity Holding Corporation’s stock is valued at $232.89 at 16:32 EST, way below its 52-week high of $276.88 and way above its 52-week low of $152.01.
More news about Paylocity Holding Corporation.
7. Uber (UBER) – 5.57%
Uber Technologies, Inc. develops and operates proprietary technology applications in the United States, Canada, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. It connects consumers with independent providers of ride services for ridesharing services; and connects riders and other consumers with restaurants, grocers, and other stores with delivery service providers for meal preparation, grocery, and other delivery services. The company operates through three segments: Mobility, Delivery, and Freight. The Mobility segment provides products that connect consumers with mobility drivers who provide rides in a range of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. It also offers financial partnerships, transit, and vehicle solutions offerings. The Delivery segment allows consumers to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered; and offers grocery, alcohol, and convenience store delivery, as well as select other goods. The Freight segment connects carriers with shippers on the company's platform and enable carriers upfront, transparent pricing, and the ability to book a shipment, as well as transportation management and other logistics services offerings. The company was formerly known as Ubercab, Inc. and changed its name to Uber Technologies, Inc. in February 2011. Uber Technologies, Inc. was founded in 2009 and is headquartered in San Francisco, California.
NYSE ended the session with Uber jumping 5.57% to $36.85 on Wednesday, after five sequential sessions in a row of gains. NYSE fell 0.54% to $15,935.31, following the last session’s upward trend on what was a somewhat down trend trading session today.
: Uber stock rises after earnings as company gives upbeat outlookShares of Uber Technologies Inc. were heading 7% higher in premarket trading Wednesday after the ride-hailing company delivered an upbeat outlook for the current quarter. , For the first quarter, Uber executives anticipate gross bookings of $31.0 billion to $32.0 billion, along with $660 million to $700 million in adjusted Ebitda.
Stocks making the biggest moves premarket: Uber, chipotle, Microsoft, lumen and moreCEO Dara Khosrowshahi said Uber ended 2022 with its strongest quarter ever, capping off its strongest year.
Uber stock earnings: UBER spike dissipates after beating Q4 consensusAfter opening as high as $37.55, up 7.6%, from Tuesday’s close, Uber (UBER) stock quickly shed most of its gains stemming from a consensus beat in its fourth quarter. , Though the level has been broken, expect it to have renewed importance as a support level should Uber stock consolidate after its January rally.
Earnings Per Share
As for profitability, Uber has a trailing twelve months EPS of $-3.86.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.71%.
Moving Average
Uber’s worth is way above its 50-day moving average of $27.81 and way above its 200-day moving average of $27.05.
More news about Uber.
8. CME Group (CME) – 5.44%
CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income products. The company also provides clearing house services, including clearing, settling, and guaranteeing futures and options contracts, and cleared swaps products traded through its exchanges; and trade processing and risk mitigation services. In addition, the company offers a range of market data services, including real-time and historical data services. It serves professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, governments, and central banks. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. CME Group Inc. was founded in 1898 and is headquartered in Chicago, Illinois.
NASDAQ ended the session with CME Group rising 5.44% to $187.46 on Wednesday while NASDAQ fell 1.68% to $11,910.52.
Earnings Per Share
As for profitability, CME Group has a trailing twelve months EPS of $5.33.
PE Ratio
CME Group has a trailing twelve months price to earnings ratio of 35.17. Meaning, the purchaser of the share is investing $35.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.65%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.9%, now sitting on 4.95B for the twelve trailing months.
More news about CME Group.
9. PGT (PGTI) – 5.41%
PGT Innovations, Inc., together with its subsidiaries manufactures and supplies impact-resistant aluminum frame windows and doors in the United States and internationally. The company provides heavy-duty aluminum or vinyl frames with laminated glass to provide protection from hurricane-force winds and wind-borne debris; and non-impact resistant vinyl windows with insulating glass and multi-chambered frames for various climate zones. It also offers customizable non-impact-resistant aluminum frame windows and doors; and non-glass vertical and horizontal sliding panels for porch enclosures, including vinyl-glazed aluminum-framed products used for enclosing screened-in porches that provide protection from inclement weather. In addition, the company provides premium aluminum impact-resistant products; aluminum impact-resistant windows and doors; vinyl energy-efficient impact-resistant windows; and commercial storefront window system and entry doors. Further, it provides impact and non-impact sliding glass and terrace doors; fixed picture, single hung, and horizontal rolling windows; aluminum thermally broken doors and windows; fixed and operating windows; sliding, folding, and hinged doors; and moving glass walls and windows. The company offers its products under the PGT, CGI, WinDoor, Western Window Systems, NewSouth, Eco Window Systems, and Anlin brands. It serves window distributors, building supply distributors, window replacement dealers, and enclosure contractors. The company was formerly known as PGT, Inc. and changed its name to PGT Innovations, Inc. in December 2016. PGT Innovations, Inc. was founded in 1980 and is headquartered in North Venice, Florida.
NASDAQ ended the session with PGT jumping 5.41% to $23.38 on Wednesday, following the last session’s upward trend. NASDAQ slid 1.68% to $11,910.52, following the last session’s upward trend on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, PGT has a trailing twelve months EPS of $0.76.
PE Ratio
PGT has a trailing twelve months price to earnings ratio of 30.76. Meaning, the purchaser of the share is investing $30.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.25%.
Sales Growth
PGT’s sales growth for the next quarter is 15.7%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 103.8% and 32.3%, respectively.
More news about PGT.
10. PDC Energy (PDCE) – 5.29%
PDC Energy, Inc., an independent exploration and production company, acquires, explores for, develops, and produces crude oil, natural gas, and natural gas liquids in the United States. The company's operations are primarily located in the Wattenberg Field in Colorado and the Delaware Basin in Texas. As of December 31, 2021, it owned interests in approximately 3,500 productive gross wells. The company was formerly known as Petroleum Development Corporation and changed its name to PDC Energy, Inc. in June 2012. PDC Energy, Inc. was founded in 1969 and is headquartered in Denver, Colorado.
NASDAQ ended the session with PDC Energy rising 5.29% to $65.52 on Wednesday while NASDAQ slid 1.68% to $11,910.52.
Earnings Per Share
As for profitability, PDC Energy has a trailing twelve months EPS of $19.39.
PE Ratio
PDC Energy has a trailing twelve months price to earnings ratio of 3.38. Meaning, the purchaser of the share is investing $3.38 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 58.28%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PDC Energy’s EBITDA is 5.64.
Revenue Growth
Year-on-year quarterly revenue growth grew by 67.8%, now sitting on 3.86B for the twelve trailing months.
More news about PDC Energy.
Losers Today
1. Lumen Technologies (LUMN) – -21.74%
Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based Ethernet, legacy data hosting services, and conferencing services. As of December 31, 2021, the company served approximately 4.5 million broadband subscribers. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. Lumen Technologies, Inc. was incorporated in 1968 and is headquartered in Monroe, Louisiana.
NYSE ended the session with Lumen Technologies falling 21.74% to $3.91 on Wednesday, after five successive sessions in a row of losses. NYSE slid 0.54% to $15,935.31, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.
Earnings Per Share
As for profitability, Lumen Technologies has a trailing twelve months EPS of $-0.709.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.68%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.4%, now sitting on 19.69B for the twelve trailing months.
Volatility
Lumen Technologies’s last week, last month’s, and last quarter’s current intraday variation average was 1.50%, 0.21%, and 2.34%.
Lumen Technologies’s highest amplitude of average volatility was 2.96% (last week), 2.82% (last month), and 2.34% (last quarter).
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Mar 6, 2022, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 8.63%.
Moving Average
Lumen Technologies’s worth is way under its 50-day moving average of $11.33 and way under its 200-day moving average of $11.96.
More news about Lumen Technologies.
2. ParkerVision (PRKR) – -21.32%
ParkerVision, Inc. develops and markets radio frequency technologies and integrated circuits for use in wireless communication products. The company was incorporated in 1989 and is headquartered in Jacksonville, Florida.
NASDAQ ended the session with ParkerVision falling 21.32% to $0.17 on Wednesday while NASDAQ dropped 1.68% to $11,910.52.
Earnings Per Share
As for profitability, ParkerVision has a trailing twelve months EPS of $-0.416.
Moving Average
ParkerVision’s worth is way under its 50-day moving average of $0.28 and way under its 200-day moving average of $0.22.
Yearly Top and Bottom Value
ParkerVision’s stock is valued at $0.17 at 16:32 EST, way below its 52-week high of $0.95 and way above its 52-week low of $0.11.
More news about ParkerVision.
3. Oxbridge Re Holdings Limited (OXBR) – -13.01%
Oxbridge Re Holdings Limited, together with its subsidiaries, provides specialty property and casualty reinsurance solutions. It underwrites reinsurance contracts primarily for property and casualty insurance companies in the Gulf Coast region of the United States. The company distributes its products and solutions through reinsurance brokers. Oxbridge Re Holdings Limited was incorporated in 2013 and is headquartered in George Town, the Cayman Islands.
NASDAQ ended the session with Oxbridge Re Holdings Limited sliding 13.01% to $2.14 on Wednesday while NASDAQ dropped 1.68% to $11,910.52.
Earnings Per Share
As for profitability, Oxbridge Re Holdings Limited has a trailing twelve months EPS of $1.38.
PE Ratio
Oxbridge Re Holdings Limited has a trailing twelve months price to earnings ratio of 1.55. Meaning, the purchaser of the share is investing $1.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.16%.
Moving Average
Oxbridge Re Holdings Limited’s value is way above its 50-day moving average of $1.88 and way below its 200-day moving average of $2.89.
More news about Oxbridge Re Holdings Limited.
4. Inovio Pharmaceuticals (INO) – -10.22%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals falling 10.22% to $1.67 on Wednesday, following the last session’s upward trend. NASDAQ slid 1.68% to $11,910.52, following the last session’s upward trend on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.073.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.99%.
Moving Average
Inovio Pharmaceuticals’s value is below its 50-day moving average of $1.80 and way below its 200-day moving average of $2.03.
Volume
Today’s last reported volume for Inovio Pharmaceuticals is 3967940 which is 27.29% below its average volume of 5457270.
More news about Inovio Pharmaceuticals.
5. Nymox Pharmaceutical Corporation (NYMX) – -8.48%
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.
NASDAQ ended the session with Nymox Pharmaceutical Corporation falling 8.48% to $0.43 on Wednesday, following the last session’s downward trend. NASDAQ dropped 1.68% to $11,910.52, following the last session’s upward trend on what was an all-around negative trend trading session today.
Earnings Per Share
As for profitability, Nymox Pharmaceutical Corporation has a trailing twelve months EPS of $-0.159.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -284.02%.
Moving Average
Nymox Pharmaceutical Corporation’s value is above its 50-day moving average of $0.41 and way below its 200-day moving average of $0.49.
Volume
Today’s last reported volume for Nymox Pharmaceutical Corporation is 62957 which is 68.43% below its average volume of 199437.
More news about Nymox Pharmaceutical Corporation.
6. Teva Pharmaceutical (TEVA) – -8.16%
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
NYSE ended the session with Teva Pharmaceutical dropping 8.16% to $10.00 on Wednesday, after two successive sessions in a row of gains. NYSE dropped 0.54% to $15,935.31, following the last session’s upward trend on what was a somewhat down trend trading session today.
Earnings Per Share
As for profitability, Teva Pharmaceutical has a trailing twelve months EPS of $-3.63.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.03%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 5.1% and a drop 7.8% for the next.
More news about Teva Pharmaceutical.
7. AMC (AMC) – -8.09%
AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. As of March 1, 2022, it operated approximately 950 theatres and 10,600 screens. The company was founded in 1920 and is headquartered in Leawood, Kansas.
NYSE ended the session with AMC falling 8.09% to $5.68 on Wednesday, after two sequential sessions in a row of losses. NYSE slid 0.54% to $15,935.31, following the last session’s upward trend on what was a somewhat bearish trend trading session today.
Earnings Per Share
As for profitability, AMC has a trailing twelve months EPS of $-39.15.
Moving Average
AMC’s value is below its 50-day moving average of $5.77 and way under its 200-day moving average of $10.59.
Sales Growth
AMC’s sales growth is 25.9% for the current quarter and 4.9% for the next.
Volume
Today’s last reported volume for AMC is 29695900 which is 6.27% below its average volume of 31685400.
Previous days news about AMC
- : AMC stock rises 14% amid meme-stock rally. According to MarketWatch on Monday, 6 February, "A meme-stock rally heated up in afternoon trading Monday, leading to a brief volatility-related halt in shares of AMC Entertainment Holdings Inc. AMC shares were halted at 3:28 p.m. "
More news about AMC.
8. Illumina (ILMN) – -8%
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
NASDAQ ended the session with Illumina sliding 8% to $198.48 on Wednesday while NASDAQ dropped 1.68% to $11,910.52.
Earnings Per Share
As for profitability, Illumina has a trailing twelve months EPS of $4.28.
PE Ratio
Illumina has a trailing twelve months price to earnings ratio of 46.37. Meaning, the purchaser of the share is investing $46.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.26%.
Previous days news about Illumina
- Do seasonals shine a light on illumina (ilmn stock)? . According to FXStreet on Tuesday, 7 February, "So, does this mean that Illumina will repeat its seasonal pattern again this year? "
More news about Illumina.
9. FuboTV (FUBO) – -7.75%
fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.
NYSE ended the session with FuboTV sliding 7.75% to $2.50 on Wednesday, after two consecutive sessions in a row of losses. NYSE fell 0.54% to $15,935.31, following the last session’s upward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, FuboTV has a trailing twelve months EPS of $-3.735.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -66.53%.
Sales Growth
FuboTV’s sales growth is 102.2% for the ongoing quarter and 99.7% for the next.
Volatility
FuboTV’s last week, last month’s, and last quarter’s current intraday variation average was 5.95%, 2.94%, and 4.89%.
FuboTV’s highest amplitude of average volatility was 6.36% (last week), 4.90% (last month), and 4.89% (last quarter).
Yearly Top and Bottom Value
FuboTV’s stock is valued at $2.50 at 16:32 EST, way under its 52-week high of $35.10 and higher than its 52-week low of $2.32.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FuboTV’s stock is considered to be overbought (>=80).
More news about FuboTV.
10. Pacific Biosciences of California (PACB) – -7.69%
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
NASDAQ ended the session with Pacific Biosciences of California dropping 7.69% to $10.39 on Wednesday, after three successive sessions in a row of losses. NASDAQ fell 1.68% to $11,910.52, following the last session’s upward trend on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Pacific Biosciences of California has a trailing twelve months EPS of $-0.34.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.76%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.9%, now sitting on 139.55M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 512.5% and a negative 9.7%, respectively.
Yearly Top and Bottom Value
Pacific Biosciences of California’s stock is valued at $10.39 at 16:32 EST, way under its 52-week high of $14.20 and way higher than its 52-week low of $3.85.
Sales Growth
Pacific Biosciences of California’s sales growth is 1.5% for the present quarter and 4.4% for the next.
More news about Pacific Biosciences of California.
Stay up to date with our winners and losers daily report
